HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation

References

• Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S-460S.
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317–325.
   PubMed Web of Science ®Google Scholar
• Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233–241.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009;29(4):431–438.
   PubMed Web of Science ®Google Scholar
• Gordon T, Kannel WB, Castelli WP, et al. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med. 1981;141(9):1128–1131.
   PubMedGoogle Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
   PubMed Web of Science ®Google Scholar
• Frohlich JJ, Pritchard PH. The clinical significance of serum high density lipoproteins. Clin Biochem. 1989;22(6):417–423.
   PubMed Web of Science ®Google Scholar
• Papageorgiou N, Tousoulis D. Is HDL a prognostic biomarker for coronary atherosclerosis? Int J Cardiol. 2014;174(3):465–467.
   PubMed Web of Science ®Google Scholar
• Milwidsky A, Kivity S, Kopel E, et al. Time dependent changes in high density lipoprotein cholesterol and cardiovascular risk. Int J Cardiol. 2014;173(2):295–299.
   PubMed Web of Science ®Google Scholar
• Favari E, Chroni A, Tietge UJ, et al. Cholesterol efflux and reverse cholesterol transport. Handb Exp Pharmacol. 2015;224:181–206.
   PubMedGoogle Scholar
• Papageorgiou N, Tousoulis D. Interaction between HDL and inflammation: when the good turns to be bad. Int J Cardiol. 2015;189:15–17.
   PubMed Web of Science ®Google Scholar
• Watanabe J, Charles-Schoeman C, Miao Y, et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum. 2012;64(6):1828–1837.
   PubMed Web of Science ®Google Scholar
• Holzer M, Wolf P, Curcic S, et al. Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res. 2012;53(8):1618–1624.
   PubMed Web of Science ®Google Scholar
• O’Neill F, Riwanto M, Charakida M, et al. Structural and functional changes in HDL with low grade and chronic inflammation. Int J Cardiol. 2015;188:111–116.
   PubMed Web of Science ®Google Scholar
• Martin SS, Khokhar AA, May HT, et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. Eur Heart J. 2015;36(1):22–30.
   PubMed Web of Science ®Google Scholar
• Marcil M, O’Connell B, Krimbou L, et al. High-density lipoproteins: multifunctional vanguards of the cardiovascular system. Expert Rev Cardiovasc Ther. 2004;2(3):417–430.
   PubMedGoogle Scholar
• Lund-Katz S, Liu L, Thuahnai ST, et al. High density lipoprotein structure. Front Biosci. 2003;8:d1044–54.
   PubMed Web of Science ®Google Scholar
• Kontush A, Lhomme M, Chapman MJ. Unraveling the complexities of the HDL lipidome. J Lipid Res. 2013;54(11):2950–2963.
   PubMed Web of Science ®Google Scholar
• Yetukuri L, Soderlund S, Koivuniemi A, et al. Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J Lipid Res. 2010;51(8):2341–2351.
   PubMed Web of Science ®Google Scholar
• Gillard BK, Lin HY, Massey JB, et al. Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. Biochim Biophys Acta. 2009;1791(12):1125–1132.
   PubMed Web of Science ®Google Scholar
• Maric J, Kiss RS, Franklin V, et al. Intracellular lipidation of newly synthesized apolipoprotein A-I in primary murine hepatocytes. J Biol Chem. 2005;280(48):39942–39949.
   PubMed Web of Science ®Google Scholar
• Nagata KO, Nakada C, Kasai RS, et al. ABCA1 dimer-monomer interconversion during HDL generation revealed by single-molecule imaging. Proc Natl Acad Sci U S A. 2013;110(13):5034–5039.
   PubMed Web of Science ®Google Scholar
• Wang N, Silver DL, Thiele C, et al. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem. 2001;276(26):23742–23747.
   PubMed Web of Science ®Google Scholar
• Timmins JM, Lee JY, Boudyguina E, et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest. 2005;115(5):1333–1342.
   PubMed Web of Science ®Google Scholar
• Brunham LR, Kruit JK, Iqbal J, et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest. 2006;116(4):1052–1062.
   PubMed Web of Science ®Google Scholar
• Denis M, Haidar B, Marcil M, et al. Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1). J Biol Chem. 2004;279(9):7384–7394.
   PubMed Web of Science ®Google Scholar
• Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22(4):336–345.
   PubMed Web of Science ®Google Scholar
• Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med. 2008;263(3):256–273.
   PubMed Web of Science ®Google Scholar
• Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7(1):53–58.
   PubMed Web of Science ®Google Scholar
• Hoeg JM, Vaisman BL, Demosky SJ Jr., et al. Lecithin:cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem. 1996;271(8):4396–4402.
   PubMed Web of Science ®Google Scholar
• Yancey PG, De La Llera-Moya M, Swarnakar S, et al. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem. 2000;275(47):36596–36604.
   PubMed Web of Science ®Google Scholar
• Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383–2393.
   PubMed Web of Science ®Google Scholar
• Khera AV, Cuchel M, De La Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127–135.
   PubMed Web of Science ®Google Scholar
• Agarwala AP, Rodrigues A, Risman M, et al. High-density lipoprotein (HDL) phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL cholesterol and coronary disease. Arterioscler Thromb Vasc Biol. 2015;35(6):1515–1519.
   PubMed Web of Science ®Google Scholar
• Li XM, Tang WH, Mosior MK, et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol. 2013;33(7):1696–1705.
   PubMed Web of Science ®Google Scholar
• Zhong Q, Zhao S, Yu B, et al. High-density lipoprotein increases the uptake of oxidized low density lipoprotein via PPARgamma/CD36 pathway in inflammatory adipocytes. Int J Biol Sci. 2015;11(3):256–265.
   PubMed Web of Science ®Google Scholar
• Calabresi L, Franceschini G, Sirtori CR, et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun. 1997;238(1):61–65.
   PubMed Web of Science ®Google Scholar
• Karabacak M, Kahraman F, Sert M, et al. Increased plasma monocyte chemoattractant protein-1 levels in patients with isolated low high-density lipoprotein cholesterol. Scand J Clin Lab Invest. 2015;75(4):327–332.
   PubMed Web of Science ®Google Scholar
• Feig JE, Rong JX, Shamir R, et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci U S A. 2011;108(17):7166–7171.
   PubMed Web of Science ®Google Scholar
• Mackness B, Mackness M. The antioxidant properties of high-density lipoproteins in atherosclerosis. Panminerva Med. 2012;54(2):83–90.
   PubMed Web of Science ®Google Scholar
• Rye KA, Barter PJ. Cardioprotective functions of HDLs. J Lipid Res. 2014;55(2):168–179.
   PubMed Web of Science ®Google Scholar
• Mackness MI, Durrington PN, Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs. 2004;4(4):211–217.
   PubMedGoogle Scholar
• Garner B, Witting PK, Waldeck AR, et al. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. J Biol Chem. 1998;273(11):6080–6087.
   PubMed Web of Science ®Google Scholar
• Zerrad-Saadi A, Therond P, Chantepie S, et al. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler Thromb Vasc Biol. 2009;29(12):2169–2175.
   PubMed Web of Science ®Google Scholar
• Maeba R, Ueta N. Ethanolamine plasmalogens prevent the oxidation of cholesterol by reducing the oxidizability of cholesterol in phospholipid bilayers. J Lipid Res. 2003;44(1):164–171.
   PubMed Web of Science ®Google Scholar
• Laurila PP, Surakka I, Sarin AP, et al. Genomic, transcriptomic, and lipidomic profiling highlights the role of inflammation in individuals with low high-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol. 2013;33(4):847–857.
   PubMed Web of Science ®Google Scholar
• Xia P, Vadas MA, Rye KA, et al. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem. 1999;274(46):33143–33147.
   PubMed Web of Science ®Google Scholar
• Sutter I, Velagapudi S, Othman A, et al. Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL. Atherosclerosis. 2015;241(2):539–546.
   PubMed Web of Science ®Google Scholar
• Kontush A. HDL-mediated mechanisms of protection in cardiovascular disease. Cardiovasc Res. 2014;103(3):341–349.
   PubMed Web of Science ®Google Scholar
• Babitt J, Trigatti B, Rigotti A, et al. Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J Biol Chem. 1997;272(20):13242–13249.
   PubMed Web of Science ®Google Scholar
• Korporaal SJ, Meurs I, Hauer AD, et al. Deletion of the high-density lipoprotein receptor scavenger receptor BI in mice modulates thrombosis susceptibility and indirectly affects platelet function by elevation of plasma free cholesterol. Arterioscler Thromb Vasc Biol. 2011;31(1):34–42.
   PubMed Web of Science ®Google Scholar
• Zhang QH, Zu XY, Cao RX, et al. An involvement of SR-B1 mediated PI3K-Akt-eNOS signaling in HDL-induced cyclooxygenase 2 expression and prostacyclin production in endothelial cells. Biochem Biophys Res Commun. 2012;420(1):17–23.
   PubMed Web of Science ®Google Scholar
• Brill A, Yesilaltay A, De Meyer SF, et al. Extrahepatic high-density lipoprotein receptor SR-BI and apoA-I protect against deep vein thrombosis in mice. Arterioscler Thromb Vasc Biol. 2012;32(8):1841–1847.
   PubMed Web of Science ®Google Scholar
• Rye KA, Barter PJ. Regulation of high-density lipoprotein metabolism. Circ Res. 2014;114(1):143–156.
   PubMed Web of Science ®Google Scholar
• Blanche PJ, Gong EL, Forte TM, et al. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta. 1981;665(3):408–419.
   PubMed Web of Science ®Google Scholar
• Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry. 1988;27(1):25–29.
   PubMed Web of Science ®Google Scholar
• Huang Y, Von Eckardstein A, Wu S, et al. A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci U S A. 1994;91(5):1834–1838.
   PubMed Web of Science ®Google Scholar
• Rye KA, Hime NJ, Barter PJ. The influence of cholesteryl ester transfer protein on the composition, size, and structure of spherical, reconstituted high density lipoproteins. J Biol Chem. 1995;270(1):189–196.
   PubMed Web of Science ®Google Scholar
• Jauhiainen M, Metso J, Pahlman R, et al. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem. 1993;268(6):4032–4036.
   PubMed Web of Science ®Google Scholar
• Barrans A, Collet X, Barbaras R, et al. Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J Biol Chem. 1994;269(15):11572–11577.
   PubMed Web of Science ®Google Scholar
• Asztalos BF, Roheim PS, Milani RL, et al. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20(12):2670–2676.
   PubMed Web of Science ®Google Scholar
• Asztalos BF, Cupples LA, Demissie S, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2004;24(11):2181–2187.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Otvos J, Nikolic D, et al. Subfractions and subpopulations of HDL: an update. Curr Med Chem. 2014;21(25):2881–2891.
   PubMed Web of Science ®Google Scholar
• Garcia-Rios A, Nikolic D, Perez-Martinez P, et al. LDL and HDL subfractions, dysfunctional HDL: treatment options. Curr Pharm Des. 2014;20(40):6249–6255.
   PubMed Web of Science ®Google Scholar
• Russo GT, Giandalia A. Markers of Systemic Inflammation and Apo-AI Containing HDL Subpopulations in Women with and without Diabetes. Int J Endocrinol. 2014;2014:607924.
   Google Scholar
• Tian L, Li C, Liu Y, et al. The value and distribution of high-density lipoprotein subclass in patients with acute coronary syndrome. PLoS One. 2014;9(1):e85114.
   PubMed Web of Science ®Google Scholar
• Du XM, Kim MJ, Hou L, et al. HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ Res. 2015;116(7):1133–1142.
   PubMed Web of Science ®Google Scholar
• Shuhei N, Soderlund S, Jauhiainen M, et al. Effect of HDL composition and particle size on the resistance of HDL to the oxidation. Lipids Health Dis. 2010;9:104.
   PubMed Web of Science ®Google Scholar
• Camont L, Lhomme M, Rached F, et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol. 2013;33(12):2715–2723.
   PubMed Web of Science ®Google Scholar
• Zeljkovic A, Vekic J, Spasojevic-Kalimanovska V, et al. Smaller HDL particles are associated with absence of obstructive coronary artery disease in stable angina pectoris patients. Ann Clin Biochem. 2014;51(Pt 3):412–415.
   PubMed Web of Science ®Google Scholar
• Joshi PH, Toth PP, Lirette ST, et al. Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. Eur J Prev Cardiol. 2016;23(1):41–49.
   Google Scholar
• De Nardo D, Labzin LI, Kono H, et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol. 2014;15(2):152–160.
   Google Scholar
• Tabet F, Vickers KC, Cuesta Torres LF, et al. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat Commun. 2014;5:3292.
   PubMed Web of Science ®Google Scholar
• Song GJ, Kim SM, Park KH, et al. SR-BI mediates high density lipoprotein (HDL)-induced anti-inflammatory effect in macrophages. Biochem Biophys Res Commun. 2015;457(1):112–118.
   PubMed Web of Science ®Google Scholar
• Tiniakou I, Drakos E, Sinatkas V, et al. High-density lipoprotein attenuates Th1 and th17 autoimmune responses by modulating dendritic cell maturation and function. J Immunol. 2015;194(10):4676–4687.
   PubMed Web of Science ®Google Scholar
• Baker PW, Rye KA, Gamble JR, et al. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J Lipid Res. 2000;41(8):1261–1267.
   PubMed Web of Science ®Google Scholar
• Litman BJ, Lewis EN, Levin IW. Packing characteristics of highly unsaturated bilayer lipids: Raman spectroscopic studies of multilamellar phosphatidylcholine dispersions. Biochemistry. 1991;30(2):313–319.
   PubMed Web of Science ®Google Scholar
• Tolle M, Pawlak A, Schuchardt M, et al. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol. 2008;28(8):1542–1548.
   PubMed Web of Science ®Google Scholar
• Galvani S, Sanson M, Blaho VA, et al. HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci Signal. 2015;8(389):ra79.
   PubMed Web of Science ®Google Scholar
• Theilmeier G, Schmidt C, Herrmann J, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation. 2006;114(13):1403–1409.
   PubMed Web of Science ®Google Scholar
• Keul P, Lucke S, Von Wnuck Lipinski K, et al. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res. 2011;108(3):314–323.
   PubMed Web of Science ®Google Scholar
• Wroblewski JM, Jahangiri A, Ji A, et al. Nascent HDL formation by hepatocytes is reduced by the concerted action of serum amyloid A and endothelial lipase. J Lipid Res. 2011;52(12):2255–2261.
   PubMed Web of Science ®Google Scholar
• Prufer N, Kleuser B, Van Der Giet M. The role of serum amyloid A and sphingosine-1-phosphate on high-density lipoprotein functionality. Biol Chem. 2015;396(6–7):573–583.
   PubMed Web of Science ®Google Scholar
• Charles-Schoeman C, Lee YY, Grijalva V, et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis. 2012;71(7):1157–1162.
   PubMed Web of Science ®Google Scholar
• Liao KP, Playford MP, Frits M, et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc. 2015 Jan 30;4(2).
   Google Scholar
• Weichhart T, Kopecky C, Kubicek M, et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol. 2012;23(5):934–947.
   PubMed Web of Science ®Google Scholar
• Kratzer A, Giral H, Landmesser U. High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease. Cardiovasc Res. 2014;103(3):350–361.
   PubMed Web of Science ®Google Scholar
• Alwaili K, Bailey D, Awan Z, et al. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta. 2012;1821(3):405–415.
   PubMed Web of Science ®Google Scholar
• Yan LR, Wang DX, Liu H, et al. A pro-atherogenic HDL profile in coronary heart disease patients: an iTRAQ labelling-based proteomic approach. PLoS One. 2014;9(5):e98368.
   PubMed Web of Science ®Google Scholar
• Dullaart RP, Annema W, Tio RA, et al. The HDL anti-inflammatory function is impaired in myocardial infarction and may predict new cardiac events independent of HDL cholesterol. Clin Chim Acta. 2014;433:34–38.
   PubMed Web of Science ®Google Scholar
• Van Lenten BJ, Hama SY, De Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96(6):2758–2767.
   PubMed Web of Science ®Google Scholar
• Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108(22):2751–2756.
   PubMed Web of Science ®Google Scholar
• Carvalho LS, Panzoldo N, Santos SN, et al. HDL levels and oxidizability during myocardial infarction are associated with reduced endothelial-mediated vasodilation and nitric oxide bioavailability. Atherosclerosis. 2014;237(2):840–846.
   PubMed Web of Science ®Google Scholar
• Ru D, Zhiqing H, Lin Z, et al. Oxidized high-density lipoprotein accelerates atherosclerosis progression by inducing the imbalance between treg and teff in LDLR knockout mice. Apmis. 2015;123(5):410–421.
   PubMed Web of Science ®Google Scholar
• Distelmaier K, Wiesbauer F, Blessberger H, et al. Impaired antioxidant HDL function is associated with premature myocardial infarction. Eur J Clin Invest. 2015;45(7):731–738.
   PubMed Web of Science ®Google Scholar
• Sattler K, Graler M, Keul P, et al. Defects of high-density lipoproteins in coronary artery disease caused by low sphingosine-1-phosphate content: correction by sphingosine-1-phosphate-Loading. J Am Coll Cardiol. 2015;66(13):1470–1485.
   PubMed Web of Science ®Google Scholar
• Stahlman M, Fagerberg B, Adiels M, et al. Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles. Biochim Biophys Acta. 2013;1831(11):1609–1617.
   PubMed Web of Science ®Google Scholar
• Denimal D, Pais De Barros JP, Petit JM, et al. Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration. Atherosclerosis. 2015;241(2):752–760.
   PubMed Web of Science ®Google Scholar
• Eren E, Yilmaz N, Aydin O. Functionally defective high-density lipoprotein and paraoxonase: a couple for endothelial dysfunction in atherosclerosis. Cholesterol. 2013;2013:792090.
   PubMedGoogle Scholar
• Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121(7):2693–2708.
   PubMed Web of Science ®Google Scholar
• Malle E, Marsche G, Panzenboeck U, et al. Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins. Arch Biochem Biophys. 2006;445(2):245–255.
   PubMed Web of Science ®Google Scholar
• Hewing B, Parathath S, Barrett T, et al. Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2014;34(4):779–789.
   PubMed Web of Science ®Google Scholar
• Hulsmans M, Holvoet P. The vicious circle between oxidative stress and inflammation in atherosclerosis. J Cell Mol Med. 2010;14(1–2):70–78.
   PubMed Web of Science ®Google Scholar
• Undurti A, Huang Y, Lupica JA, et al. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem. 2009;284(45):30825–30835.
   PubMed Web of Science ®Google Scholar
• Soumyarani VS, Jayakumari N. Oxidatively modified high density lipoprotein promotes inflammatory response in human monocytes-macrophages by enhanced production of ROS, TNF-α, MMP-9, and MMP-2. Mol Cell Biochem. 2012;366(1–2):277–285.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ji L, Jiang R, et al. Oxidized high-density lipoprotein induces the proliferation and migration of vascular smooth muscle cells by promoting the production of ROS. J Atheroscler Thromb. 2014;21(3):204–216.
   PubMed Web of Science ®Google Scholar
• Huang Y, Wu Z, Riwanto M, et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest. 2013;123(9):3815–3828.
   PubMed Web of Science ®Google Scholar
• Acharjee S, Boden WE, Hartigan PM, et al. Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE trial (clinical outcomes utilizing revascularization and aggressive drug evaluation). J Am Coll Cardiol. 2013;62(20):1826–1833.
   PubMed Web of Science ®Google Scholar
• Toth PP, Barylski M, Nikolic D, et al. Should low high-density lipoprotein cholesterol (HDL-C) be treated? Best Pract Res Clin Endocrinol Metab. 2014;28(3):353–368.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–2099.
   PubMed Web of Science ®Google Scholar
• Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267.
   PubMed Web of Science ®Google Scholar
• Angeloni E, Paneni F, Landmesser U, et al. Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J. 2013;34(46):3557–3562.
   PubMed Web of Science ®Google Scholar
• Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572–580.
   PubMed Web of Science ®Google Scholar
• Huang Y, DiDonato JA, Levison BS, et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med. 2014;20(2):193–203.
   PubMed Web of Science ®Google Scholar
• Haraguchi Y, Toh R, Hasokawa M, et al. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease. Atherosclerosis. 2014;234(2):288–294.
   PubMed Web of Science ®Google Scholar
• Perez-Mendez O, Pacheco HG, Martinez-Sanchez C, et al. HDL-cholesterol in coronary artery disease risk: function or structure? Clin Chim Acta. 2014;429:111–122.
   PubMed Web of Science ®Google Scholar
• Ashmaig ME, Gupta S, McConnell JP, et al. Validation of a novel homogeneous assay for of HDL3-C measurement. Clin Chim Acta. 2013;425:37–41.
   PubMed Web of Science ®Google Scholar
• Barylski M, Toth PP, Nikolic D, et al. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract Res Clin Endocrinol Metab. 2014;28(3):453–461.
   PubMed Web of Science ®Google Scholar
• Smith JD. Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis. Curr Opin Investig Drugs. 2010;11(9):989–996.
   PubMedGoogle Scholar
• Nguyen SD, Javanainen M, Rissanen S, et al. Apolipoprotein A-I mimetic peptide 4F blocks sphingomyelinase-induced LDL aggregation. J Lipid Res. 2015;56(6):1206–1221.
   PubMed Web of Science ®Google Scholar
• Morgantini C, Imaizumi S, Grijalva V, et al. Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes. Diabetes. 2010;59(12):3223–3228.
   PubMed Web of Science ®Google Scholar
• Amar MJ, D’Souza W, Turner S, et al. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther. 2010;334(2):634–641.
   PubMed Web of Science ®Google Scholar
• Bloedon LT, Dunbar R, Duffy D, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res. 2008;49(6):1344–1352.
   PubMed Web of Science ®Google Scholar
• Lund EG, Menke JG, Sparrow CP. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23(7):1169–1177.
   PubMed Web of Science ®Google Scholar
• Saddar S, Mineo C, Shaul PW. Signaling by the high-affinity HDL receptor scavenger receptor B type I. Arterioscler Thromb Vasc Biol. 2010;30(2):144–150.
   PubMed Web of Science ®Google Scholar
• Nikolic D, Rizzo M, Mikhailidis DP, et al. An evaluation of RVX-208 for the treatment of atherosclerosis. Expert Opin Investig Drugs. 2015;24(10):1389–1398.
   PubMed Web of Science ®Google Scholar
• Al-Allaf FA, Coutelle C, Waddington SN, et al. LDLR-gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives. Int Arch Med. 2010;3:36.
   PubMedGoogle Scholar
• Flores-Castillo C, Zamora-Perez JA, Carreon-Torres E, et al. Atorvastatin and fenofibrate combination induces the predominance of the large HDL subclasses and increased apo AI fractional catabolic rates in New Zealand white rabbits with exogenous hypercholesterolemia. Fundam Clin Pharmacol. 2015;29(4):362–370.
   PubMed Web of Science ®Google Scholar
• Berthold HK, Rizzo M, Spenrath N, et al. Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial. PLoS One. 2014;9(3):e91565.
   Google Scholar
• Rallidis LS, Tellis CC, Lekakis J, et al. Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. J Am Coll Cardiol. 2012;60(20):2053–2060.
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Nasser SA. PCSK9 inhibition: discovery, current evidence, and potential effects on LDL-C and Lp(a). Cardiovasc Drugs Ther. 2015;29(3):295–308.
   PubMed Web of Science ®Google Scholar
• Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. Jama. 1975;231:360–381.
   PubMed Web of Science ®Google Scholar
• HPS2-THRIVE Collaborative GroupLandray MJ, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371: 203–212.
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–3517.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861.
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med. 1999;341:410–418.
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237–1245.
   PubMed Web of Science ®Google Scholar
• Frick MH, Heinonen OP, Huttunen JK. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann Med. 1993;25:41–45.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Me. 2007;356:1304–1316.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25):2406–2415.
   Google Scholar
• Schwartz GG, Olsson AG, Abt M, et al; dal-OUTCOMES investigators effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099.
   PubMed Web of Science ®Google Scholar
• Zaid M, Fujiyoshi A, Miura K, et al,; SESSA Research group. High-density lipoprotein particle concentration and subclinical atherosclerosis of the carotid arteries in Japanese men. Atherosclerosis. 2015;239:444–450.
   PubMed Web of Science ®Google Scholar
• Tardif JC, Grégoire J, L’Allier PL, et al. Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. Jama. 2007;297:1675–1682.
   PubMed Web of Science ®Google Scholar
• Grover SA, Kaouache M, Joseph L, et al. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Arch Intern Med. 2009;169:1775–1780.
   PubMedGoogle Scholar
• Kaur N, Pandey A, Negi H, et al. Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression. PLoS One. 2014;9:e94585.
   PubMed Web of Science ®Google Scholar
• Alagona C, Soro A, Westerbacka J, et al. Low HDL cholesterol concentration is associated with increased intima-media thickness independent of arterial stiffness in healthy subjects from families with low HDL cholesterol. Eur J Clin Invest. 2003;33:457–463.
   PubMed Web of Science ®Google Scholar
• Sharrett AR, Ballantyne CM, Coady SA, et al.; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis risk in Communities (ARIC) Study. Circulation. 2001;104:1108–1113.
   PubMed Web of Science ®Google Scholar
• Guyton JR, Slee AE, Anderson T, et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides and impact on global health outcomes). J Am Coll Cardiol. 2013;62:1580–1584.
   PubMed Web of Science ®Google Scholar
• Williams PT, Feldman DE. Prospective study of coronary heart disease vs HDL2, HDL3, and other lipoproteins in Gofman’s Livermore Cohort. Atherosclerosis. 2011;214:196–202.
   PubMed Web of Science ®Google Scholar
• Nichols GA, Koro CE, Chan W, et al. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up. Clin Ther. 2006;28:243–250.
   PubMed Web of Science ®Google Scholar
• Ericsson CG, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post infarction patients. Lancet. 1996;347:849–853.
   PubMed Web of Science ®Google Scholar
• Virani SS, Catellier DJ, Pompeii LA, et al. Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study. Atherosclerosis. 2011;219:596–602.
   PubMed Web of Science ®Google Scholar
• Bays H, Giezek H, McKenney JM, et al. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metab Syndr Relat Disord. 2012;10:260–266.
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–92116.
   PubMed Web of Science ®Google Scholar
• Williams PT. Low high-density lipoprotein 3 reduces the odds of men surviving to age 85 during 53-year follow-up. J Am Geriatr Soc. 2012;60:430–436.
   PubMed Web of Science ®Google Scholar
• Phan BA, Moore AB, Davis J, et al. Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: a case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS). J Clin Lipidol. 2014;8:489–493.
   PubMed Web of Science ®Google Scholar
• Scoffone HM, Krajewski M, Zorca S, et al. Effect of extended-release niacin on serum lipids and on endothelial function in adults with sickle cell anemia and low high-density lipoprotein cholesterol levels. Am J Cardiol. 2013;112:1499–1504.
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–1298.
   PubMed Web of Science ®Google Scholar
• Mackey RH, Greenland P, Goff DC Jr, et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol. 2012;60:508–516.
   PubMed Web of Science ®Google Scholar
• Frick MH, Syvänne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation. 1997;96:2137–2143.
   PubMed Web of Science ®Google Scholar
• Alagona C, Soro A, Ylitalo K, et al. A low high density lipoprotein (HDL) level is associated with carotid artery intima-media thickness in asymptomatic members of low HDL families. Atherosclerosis. 2002;165:309–316.
   PubMed Web of Science ®Google Scholar
• Araujo AB, Chiu GR, Christian JB, et al. Longitudinal changes in high-density lipoprotein cholesterol and cardiovascular events in older adults. Clin Endocrinol (Oxf). 2014;80A:662–670.
   Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-ensity Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–418.
   PubMed Web of Science ®Google Scholar
• Mora S, Otvos JD, Rifai N, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119:931–939.
   PubMed Web of Science ®Google Scholar
• Katakami N, Kaneto H, Osonoi T, et al. Usefulness of lipoprotein ratios in assessing carotid atherosclerosis in Japanese type 2 diabetic patients. Atherosclerosis. 2011;214:442–447.
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Rubins HB, Robins SJ, et al. Carotid atherosclerosis in men with low levels of HDL cholesterol. Stroke. 1997;28:1919–1925.
   PubMed Web of Science ®Google Scholar